Prematural Retinopathy (ROP)
Who is it for?
In ROP preterm babies, because the vascular development in the retina layer of the eye is not completed, abnormal vascular development occurs and as a result, bleeding, scar tissue and retinal detachment may develop, which may result in blindness. However, these abnormal vessels often regress, only about 10% of babies have enough progress to require treatment. ROP is usually seen in babies born under 32 weeks and low birth weight below 1500 g. The risk is higher in babies who require additional oxygen therapy in an incubator after birth.
All babies born younger than 32 weeks and below 1500 grams, and preterm babies who were given cardiopulmonary support therapy even though they were born above 32 weeks and above 1500 grams or who were “at risk for the development of ROP by the clinician following the baby” within 4-6 weeks after birth ( early 30th week) ROP screening examination should be done . After these examinations, babies diagnosed with ROP are followed up at necessary intervals according to their stages until retinal vessel development is completed. While laser treatment is the gold standard when treatment is required, in some cases where laser is not possible, anti-VEGF injection may also be required.
In our hospital’s ROP diagnosis-treatment center, ROP scans and treatments are performed by a large group of doctors in collaboration with pediatric ophthalmology and retina units. All babies born prematurely and requiring eye screening, postnatal 4-6. After the retinal scans are performed and completed at the required frequency starting from the 1st week, annual regular follow-ups from the 1st year to the age of 5 are also done in our ROP polyclinic. In our ROP center, we have laser compatible indirect ophthalmoscope used for diagnosis and treatment and 810 nm diode laser devices used in ROP treatment. Our center will carry its experience in ROP diagnosis, follow-up and treatment further with the arrival of the digital color fundus imaging device, which we have requested for the follow-up of vascular development and the objective evaluation of the effects of the treatments.